Brand Name Justification - Dectomax 500mL Injectable Solution

United States Department of Agriculture
Justification for Other than Full and Open Competition
Identification Number: 1174070
Pursuant to the requirements of the Competition in Contracting Act as implemented by Revolutionary Federal Acquisition Regulation (FAR) Overhaul (RFO) FAR Part 6 and in accordance with the requirements of RFO FAR 6.104-1, the justification for the use of the statutory authority cited herein is supported by the following facts and rationale: (1) Mission Area and Contracting Activity.
The United States Department of Agriculture, Animal Plant Health Inspection Service (APHIS), Marketing Regulatory Programs Business Services, Acquisition and Asset Management Division, Acquisition Branch, proposes to enter into a contract on a basis other than full and open competition (Brand Name), on behalf of Animal Plant Health Inspection Service, Veterinary Services, Cattle Fever Tick Eradication Program (CFTEP).
(2) Nature and/or description of the action being approved: This J&A authorizes and approves the solicitation and award of a firm-fixed price one-time commercial purchase of a veterinary pharmaceutical product on a brand-name only basis. T under the Revolutionary FAR Overhaul (RFO) Part 12 streamlined procedures for commercial products.
(3) A description of the supplies or services required to meet the agency’s needs (including the estimated value).
APHIS intends to award a firm‑fixed‑price, brand‑name‑only purchase order for Dectomax® 1% doramectin injectable, 500 mL using commercial item simplified procedures under 41 U.S.C. 1901 (RFO FAR Part 12). Estimated value: $400,800.
(4) Identify the statutory authority permitting other than full and open competition. The statutory authority permitting other than full and open competition is 10 U.S.C. 2304(c) (1) as implemented by FAR FAR 6.103-1 (d), Brand Name
(5) Demonstrate that the proposed contractor's unique qualifications or the nature of the acquisition requires using the authority cited.
APHIS has determined that Dectomax® 1% Injectable Solution (doramectin) possesses unique capabilities that are essential to our requirements, and no other product meets these needs. The critical distinguishing requirement is the route of administration and formulation: the product must be an injectable formulation of doramectin (or an equally effective systemic endectocide). This requirement arises from the specific needs of APHIS’s cattle fever tick and screwworm programs: